Gracell Biotechnologies (GRCL) Short Interest Ratio & Short Volume

Short interest is the volume of Gracell Biotechnologies shares that have been sold short but have not yet been covered or closed out. As of November 15th, traders have sold 922,400 shares of GRCL short. 1.29% of Gracell Biotechnologies' shares are currently sold short. Learn More on Gracell Biotechnologies' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GRCL shares currently have a short interest ratio of 2.0. Learn More on Gracell Biotechnologies's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Gracell Biotechnologies: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.29% of Gracell Biotechnologies' floating shares are currently sold short.

Gracell Biotechnologies saw a increase in short interest in November. As of November 15th, there was short interest totaling 922,400 shares, an increase of 2.6% from the previous total of 898,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Gracell Biotechnologies currently has issued a total of 72,680,000 shares. Some of Gracell Biotechnologies' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Gracell Biotechnologies currently has a public float of 71,320,000 shares.

1.29% of Gracell Biotechnologies' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Gracell Biotechnologies: Immunome, Inc. (1.00%), uniQure (8.77%), Nature's Sunshine Products, Inc. (0.31%), Harrow Health, Inc. (17.40%), IGM Biosciences, Inc. (20.03%), Arbutus Biopharma Co. (4.01%), Marinus Pharmaceuticals, Inc. (8.34%), Organogenesis Holdings Inc. (5.97%), Avid Bioservices, Inc. (9.68%), UroGen Pharma Ltd. (12.07%),

As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($7.24 billion), T-Mobile US, Inc. ($4.02 billion), Charter Communications, Inc. ($3.72 billion), Occidental Petroleum Co. ($2.80 billion), Lululemon Athletica Inc. ($2.48 billion), Coinbase Global, Inc. ($2.38 billion), Tractor Supply ($2.35 billion), Rivian Automotive, Inc. ($1.79 billion), Royal Caribbean Cruises Ltd. ($1.73 billion), and Moderna, Inc. ($1.71 billion). View all of the most shorted stocks.

Short selling GRCL is an investing strategy that aims to generate trading profit from Gracell Biotechnologies as its price is falling. GRCL shares are trading up $0.40 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Gracell Biotechnologies occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GRCL, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GRCL, twice per month. The most recent reporting period available is November, 15 2023.